Argen offers Selective Laser Melted (SLM) copings in high noble, noble and non-precious, Digital Precious Metals in 20 of Argen’s Most Popular Alloys, Argen®Mill milled gold crowns, SLM Captek, ArgenIS Custom Abutments, ArgenZ Zirconia discs and milled units, Digital Models, ArgenPMMA Temps, ArgenWAX and Digital Scanners. Argen’s innovative digital services provide the most complete digital solutions to dental laboratories of all sizes. Today, Argen Digital has grown to over 100 printing and milling machines running 24 hours per day, 6 days per week serviced by over 150 people. Today, Argen’s 40,000 square foot facility houses alloy production, Argen Refining, Zirconia Manufacturing and Argen Digital. above or below their isoelectric point.By 2010, Anton had positioned the company to start fully integrating into digital and by 2011 Argen officially opened the digital outsourcing center – Argen Digital. Formulation development teams can use kinetic data collected by ARGEN to see differences in AR within solutions containing surface charged and surface neutral proteins, i.e. This application note summarizes the use of ARGEN to determine colloidal stability for Bovine Serum Albumin (BSA) at three different solution pH levels. The aggregation or degradation rate offers a valuable and accurate measurement for colloidal stability for protein formulations and polymer solutions. Furthermore, since all data is generated continuously and in real time, ARGEN analysis methods can determine the kinetic Aggregation Rate (AR) for each sample independently. This enables them to identify the onset of aggregation, degradation, or a phase change more rapidly than with other technologies.
Researchers using ARGEN can quickly detect changes in the relative molecular weight for molecules in solution.
This allows the benefit of expediting formulation exploration and development. Testing each sample independently allows for control and rapid characterization of multiple stress conditions in each study. Additionally, ARGEN users can introduce and remove samples from testing without affecting other ongoing measurements.
Because most therapeutic protein formulations are difficult and expensive to produce at high yields, biopharma companies need tools that provide rapid, high quality protein stability information with low sample consumption.ĪRGEN is a light scattering instrument with 16 independent sample cells that allow multiple, independent experiments, each one with its own stress conditions. For each therapeutic, biopharma companies use formulation development to search for the unique “goldilocks zone” where the solution is stable in all the required conditions. This trade space includes factors such as solvent choice, ionic strength, pH, concentration and excipients. To mitigate against protein degradation, drug companies employ formulation development.Ī formulation is one solution condition in a multidimensional therapeutic trade space. The challenge for biopharmaceutical companies is that degraded proteins create ineffective and potentially harmful therapeutics for their customers. Unstable proteins are more prone to degradation from the primary stress mechanisms: mechanical and thermal (from manufacturing, storage and transport) and biological (from drug delivery). Unfortunately, when removed from their native environments, proteins become less stable. Biopharmaceutical companies isolate many types of proteins for use in experimental and therapeutic medicines.
0 kommentar(er)
